Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.70
- Piotroski Score 7.00
- Grade Hold
- Symbol (GILD)
- Company Gilead Sciences, Inc.
- Price $88.60
- Changes Percentage (0.97%)
- Change $0.85
- Day Low $87.77
- Day High $89.07
- Year High $98.90
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Last Earnings 11/06/2024
- Ex-Dividend for 5/16 Dividend 12/13/2024
- Dividend Payable 12/30/2024
- Today N/A
- Next Earnings (Estimated) 02/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $83.50
- High Stock Price Target $105.00
- Low Stock Price Target $54.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.36
- Trailing P/E Ratio 179.72
- Forward P/E Ratio 179.72
- P/E Growth 179.72
- Net Income $5.67 B
Income Statement
Quarterly
Annual
Latest News of GILD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Russian oligarch poised to sell gilded NYC penthouse in an all-cash deal -- amid a massive global property sell-off
Billionaire Valery Kogan and wife Olga are selling their luxurious Central Park West apartment at a discounted price amidst a real estate sell-off. The property boasts stunning views and extravagant f...
By Yahoo! Finance | 8 hours ago -
Exclusive | Russian oligarch poised to sell gilded NYC penthouse in an all-cash...
Russian billionaire Valery Kogan and his wife Olga are selling their luxurious property at 15 Central Park West in a cash deal....
By New York Post | 1 day ago -
Should You Buy Gildan Activewear Inc. (TSE:GIL) For Its Upcoming Dividend?
Gildan Activewear Inc. (TSE:GIL) is trading ex-dividend soon, with a payment of US$0.205 per share on December 16. Dividend sustainability is key, with Gildan covering it through profit and cash flow....
By Yahoo! Finance | 3 days ago
